| Date:September 17th 2021 |
|---|
| Your Name:Shuguang Pang |
| Manuscript Title: <u>Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective</u> |
| real-world study in China |
| Manuscript number (if known): |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | XNone | |
|----|---|-----------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |
| | lectures, presentations, | | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| - | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ X None | |
| | pending | | |
| 9 | Participation on a Data | V N | |
| 9 | Safety Monitoring Board or | X None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| _ | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| 12 | Receipt of equipment, | X None | |
| 12 | materials, drugs, medical | X None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116).

Please place an "X" next to the following statement to indicate your agreement:

| Date:September 17th 2021 |
|---|
| Your Name:Qiang |
| Manuscript Title: <u>Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective</u> |
| real-world study in China |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | XNone | |
|----|---|---------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert | X None | |
| 0 | testimony | ^ NONE | |
| | | | |
| 7 | Support for attending | XNone | |
| - | meetings and/or travel | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | XNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116).

Please place an "X" next to the following statement to indicate your agreement:

| Date:September 17th 2021 |
|---|
| Your Name: <u>Pei_Sun</u> |
| Manuscript Title: <u>Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective</u> |
| real-world study in China |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | - | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | XNone | |
|----|---|---------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert | X None | |
| 0 | testimony | ^ NONE | |
| | | | |
| 7 | Support for attending | XNone | |
| - | meetings and/or travel | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | XNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | X None | |
| | financial interests | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116).

Please place an "X" next to the following statement to indicate your agreement:

| Date:September 17th 2021 |
|---|
| Your Name:Yi_Li |
| Manuscript Title: <u>Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective</u> |
| real-world study in China |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | - | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | XNone | |
|----|---|-----------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | X None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ X None | |
| | pending | | |
| 9 | Participation on a Data | V. Nasa | |
| 9 | Safety Monitoring Board or | XNone | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | M | |
| 11 | Stock or stock options | XNone | |
| | | | |
| 12 | Receipt of equipment, | X None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | | Yi Li is from Jiangsu Hengrui Pharmaceuticals Co., Ltd |
| | financial interests | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). Yi Li is from Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| Date:September 17th 2021 |
|---|
| Your Name:Yanhua_Zhu |
| Manuscript Title: <u>Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective</u> |
| real-world study in China |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | - | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | X None | |
|----|--|---------------|--|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | XNone | |
| 13 | Other financial or non- financial interests | | Yanhua Zhu is from Jiangsu Hengrui Pharmaceuticals Co., Ltd |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). Yanhua Zhu is from Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| Date:September 17th 2021 |
|---|
| Your Name: |
| Manuscript Title: <u>Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective</u> |
| real-world study in China |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone | |
|----|---|----------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert | X None | |
| 0 | testimony | ^ NONE | |
| | cestimony | | |
| 7 | Support for attending | XNone | |
| | meetings and/or travel | | |
| | C . | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X None | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | X _None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | | Jin Liu is from Jiangsu Hengrui Pharmaceuticals Co., Ltd |
| | financial interests | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). Jin Liu is from Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | X None | |
|----|---|-----------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | X _None | |
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X _None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | - | | |
| | | | |
| 8 | Patents planned, issued or | _ X None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data Safety Monitoring Board or | X None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| 12 | Receipt of equipment, | X None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | | Xiaoran Ye is from Shanghai Palan DataRx Co., Ltd. |
| | financial interests | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). Xiaoran Ye is from Shanghai Palan DataRx Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| Date:September 17th 2021 |
|---|
| Your Name: |
| Manuscript Title: <u>Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective</u> |
| real-world study in China |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | X None | |
|----|---|-----------------|---|
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |
| | lectures, presentations, | | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| - | testimony | | |
| | - | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ X None | |
| | pending | | |
| 0 | Destinization on a Data | M | |
| 9 | Participation on a Data Safety Monitoring Board or | X None | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | X None | |
| 10 | in other board, society, | X None | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | X None | |
| | | | |
| 40 | | M | |
| 12 | Receipt of equipment, materials, drugs, medical | X None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | | Ting Chen is from Shanghai Palan DataRx Co., Ltd. |
| | financial interests | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). Ting Chen is from Shanghai Palan DataRx Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| Date:September | 17th 2021 |
|-----------------------|--|
| Your Name: <u>Fei</u> | Zhao |
| Manuscript Title: | Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective |
| real-world study in | China |
| Manuscript number | r (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | X None | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | X None | |
|----|--|----------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |
| | lectures, presentations, | | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | XNone | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X _None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | V. Nore | |
| 10 | in other board, society, | XNone | |
| | committee or advocacy | | |
| | , group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | X None | |
| | materials, drugs, medical writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | | Fei Zhao is from Shandong Health Medical Big Data Co., |
| | financial interests | | Ltd. |
| | | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). Fei Zhao is from Shandong Health Medical Big Data Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

| Date:September 17th 2021 |
|---|
| Your Name:Wenjun Yang |
| Manuscript Title: <u>Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective</u> |
| real-world study in China |
| Manuscript number (if known): |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|--|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116). |
| | - | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X None | |

| 4 | Consulting fees | XNone | |
|----|--|----------------|--|
| | | | |
| | | | |
| 5 | Payment or honoraria for | X None | |
| | lectures, presentations, | | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | X None | |
| | testimony | | |
| | | | |
| 7 | Support for attending | XNone | |
| | meetings and/or travel | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | _ XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | X _None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | Y News | |
| 10 | in other board, society, | X None | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | XNone | |
| | materials, drugs, medical | | |
| | writing, gifts or other services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |

This study was funded by the Key Technology Research and Development Program of Shandong (2016GSF201019) and the Jinan Science and Technology Bureau (201704116).

Please place an "X" next to the following statement to indicate your agreement: